LineaRx Publishes Manuscript Demonstrating that a LinearDNA™ Vaccine Candidate was Protective in Virus Challenge Trial in Ferrets
September 30, 2022
LineaRx and EvviVax Publish Additional Positive Animal Proof-of-Concept Data Supporting LinearDNA™ Platform as a Unique Approach to Veterinary DNA Vaccine Development
July 25, 2022
APDN, Evvivax Announce LinearDNA™ Vaccine Candidate Booster Yields 5-Fold Average Increase in Neutralizing Antibody Titers in Domestic Felines
May 6, 2021
APDN and Takis Biotech/Evvivax to Launch Clinical Trial for Veterinary Use of Linear COVID-19 Vaccine Candidate
September 16, 2020
APDN and Takis Report Positive Preclinical Results from LineaDNA™ Vaccine Candidates for COVID-19
July 17, 2020
APDN and Takis Biotech Announce the Production of Neutralizing Antibodies Against SARS-CoV-2 After DNA Vaccination in Animals
May 4, 2020
APDN Ships COVID-19 LinearDNA™ Vaccine Candidates to Italian Development Partner to Begin Preclinical Animal Testing
April 15, 2020
APDN Updates on COVID-19 Collaboration with Takis Biotech, 4 Preclinical LinearDNA™ Vaccine Candidates Designed
March 2, 2020
LineaRx and Takis Biotech Collaborate for Development of a Linear DNA Vaccine Candidate Against Wuhan Coronavirus 2019-nCoV
February 7, 2020
LineaRx and Takis/Evvivax Anti-Cancer Vaccine Candidates Demonstrate Tumor Reduction
September 19, 2019